Chimerix (CMRX) Appoints Marc D. Kozin to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
Chimerix Appoints Marc D. Kozin to Board of Directors
March 21, 2024 7:00 AM EDTDURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Marc D. Kozin as the newest member of the Companys Board of Directors. In addition, Patrick Machado has announced his retirement from the Chimerix Board effective at the Companys 2024 Annual Meeting of Stockholders in June, after ten years of service.
We are pleased to welcome Marc to the Board of Directors. Marcs strategic insights and... More
